Do Aromatase Inhibitors Cause Cognitive Decline? A Look at the Evidence
•
5 min read
More than 3.5 million breast cancer survivors in the U.S. have taken aromatase inhibitors (AIs), a crucial therapy that has also raised questions about potential cognitive decline, or 'chemobrain,' experienced by some patients. While anecdotal reports are common, the scientific evidence addressing whether aromatase inhibitors cause cognitive decline remains complex and, in some cases, conflicting.
